Research & Development
EMA evaluates extended use of COVID-19 drug remdesivir
23 February 2021 -

The European Medicines Agency (EMA), Europe's drugs regulator, said on 23 February 2021 that it is evaluating the use of remdesivir in COVID-19 patients who do not need oxygen support, Reuters news agency reported on Tuesday.

This reportedly comes after Gilead Sciences, a US biopharmaceutical company researching antiviral drugs and the developer of remdesivir, submitted an application to extend the medicine's use.

Europe had earlier conditionally approved remdesivir, sold under the brand name Veklury, in July 2021 for treating COVID-19 in adults and adolescents with pneumonia requiring oxygen support, Reuters added.



Related Headlines